Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022

Adi V Gundlapalli; Susan E Beekmann; Jefferson M Jones; Natalie J Thornburg; Kristie E N Clarke; Timothy M Uyeki; Panayampalli S Satheshkumar; Darin S Carroll; Ian D Plumb; Melissa Briggs-Hagen; Scott Santibañez; Corinne David-Ferdon; Philip M Polgreen; L Clifford McDonald

doi:10.1093/ofid/ofad091

Back

Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022

Journal article

Open access

Peer reviewed

Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022

Adi V Gundlapalli, Susan E Beekmann, Jefferson M Jones, Natalie J Thornburg, Kristie E N Clarke, Timothy M Uyeki, Panayampalli S Satheshkumar, Darin S Carroll, Ian D Plumb, Melissa Briggs-Hagen, …

Open forum infectious diseases, Vol.10(3), ofad091

03/2023

DOI: 10.1093/ofid/ofad091

PMCID: PMC10026543

PMID: 36949879

Files and links (1)

url

https://doi.org/10.1093/ofid/ofad091View

Published (Version of record) Open Access

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody tests have had limited recommended clinical application during the coronavirus disease 2019 (COVID-19) pandemic. To inform clinical practice, an understanding is needed of current perspectives of United States-based infectious disease (ID) physicians on the use, interpretation, and need for SARS-CoV-2 antibody tests. In March 2022, members of the Emerging Infections Network (EIN), a national network of practicing ID physicians, were surveyed on types of SARS-CoV-2 antibody assays ordered, interpretation of test results, and clinical scenarios for which antibody tests were considered. Of 1867 active EIN members, 747 (40%) responded. Among the 583 who managed or consulted on COVID-19 patients, a majority (434/583 [75%]) had ordered SARS-CoV-2 antibody tests and were comfortable interpreting positive (452/578 [78%]) and negative (405/562 [72%]) results. Antibody tests were used for diagnosing post-COVID-19 conditions (61%), identifying prior SARS-CoV-2 infection (60%), and differentiating prior infection and response to COVID-19 vaccination (37%). Less than a third of respondents had used antibody tests to assess need for additional vaccines or risk stratification. Lack of sufficient evidence for use and nonstandardized assays were among the most common barriers for ordering tests. Respondents indicated that statements from professional societies and government agencies would influence their decision to order SARS-CoV-2 antibody tests for clinical decision making. Practicing ID physicians are using SARS-CoV-2 antibody tests, and there is an unmet need for clarifying the appropriate use of these tests in clinical practice. Professional societies and US government agencies can support clinicians in the community through the creation of appropriate guidance.

Serology

COVID-19

SARS-CoV-2

antibody tests

utilization

Details

Title: Subtitle: Use of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Tests by US Infectious Disease Physicians: Results of an Emerging Infections Network Survey, March 2022
Creators: Adi V Gundlapalli - Centers for Disease Control and Prevention
Susan E Beekmann - University of Iowa
Jefferson M Jones - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Natalie J Thornburg - Centers for Disease Control and Prevention
Kristie E N Clarke - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Timothy M Uyeki - Centers for Disease Control and Prevention
Panayampalli S Satheshkumar - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Darin S Carroll - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Ian D Plumb - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Melissa Briggs-Hagen - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Scott Santibañez - Centers for Disease Control and Prevention
Corinne David-Ferdon - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Philip M Polgreen - University of Iowa
L Clifford McDonald - COVID-19 Emergency Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Resource Type: Journal article
Publication Details: Open forum infectious diseases, Vol.10(3), ofad091
DOI: 10.1093/ofid/ofad091
PMID: 36949879
PMCID: PMC10026543
NLM abbreviation: Open Forum Infect Dis
ISSN: 2328-8957
eISSN: 2328-8957
Grant note: DOI: 10.13039/100000030, name: Centers for Disease Control and Prevention, award: 1 U50 CK00477
Language: English
Date published: 03/2023
Academic Unit: Infectious Diseases; Epidemiology; Injury Prevention Research Center; Internal Medicine
Record Identifier: 9984380659502771

Metrics

5 Record Views

See more details